Role of glutathione S-transferases in melanoma susceptibility: Association with GSTP1 rs1695 polymorphism

British Journal of Dermatology

Volumn 166, Issue 6, 2012, Pages 1176-1183

  Ibarrola Villava, M ^a   Martin Gonzalez, M ^b   Lazaro, P ^c   Pizarro, A ^d   Lluch, A ^a   Ribas, G ^a  

^a Instituto Universitario IVI INCLIVA   (Spain)

^b HOSPITAL RAMÓN Y CAJAL   (Spain)

^c HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^d HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; GLUTATHIONE TRANSFERASE; GLUTATHIONE TRANSFERASE M1; GLUTATHIONE TRANSFERASE P1; GLUTATHIONE TRANSFERASE T1; ISOLEUCINE; VALINE;

ALLELE; AMINO ACID SUBSTITUTION; ARTICLE; CANCER PATIENT; CANCER SUSCEPTIBILITY; CASE CONTROL STUDY; CONTROLLED STUDY; COPY NUMBER VARIATION; DIAGNOSTIC TEST ACCURACY STUDY; GENE EXPRESSION; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MELANOMA; MOLECULAR PROBE; MULTICENTER STUDY; PRIORITY JOURNAL; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; SPAIN;

CASE-CONTROL STUDIES; DNA COPY NUMBER VARIATIONS; EYE COLOR; FEMALE; GENE DELETION; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GLUTATHIONE S-TRANSFERASE PI; GLUTATHIONE TRANSFERASE; HAIR COLOR; HUMANS; MALE; MELANOMA; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTOR, MELANOCORTIN, TYPE 1; RISK FACTORS; SKIN NEOPLASMS; SPAIN;

EID: 84861593805     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2012.10831.x     Document Type: Article

References (40)

1. Saenz S, Conejo-Mir J, Cayuela A,. Melanoma epidemiology in Spain. Actas Dermosifiliogr 2005; 96: 411-18.
2. Bataille V,. Genetic epidemiology of melanoma. Eur J Cancer 2003; 39: 1341-7.
3. Valverde P, Healy E, Jackson I, et al. Variants of the melanocyte-stimulating hormone receptor gene are associated with red hair and fair skin in humans. Nat Genet 1995; 11: 328-30.
4. Matichard E, Verpillat P, Meziani R, et al. Melanocortin 1 receptor (MC1R) gene variants may increase the risk of melanoma in France independently of clinical risk factors and UV exposure. J Med Genet 2004; 41: e13.
5. Fargnoli MC, Altobelli E, Keller G, et al. Contribution of melanocortin-1 receptor gene variants to sporadic cutaneous melanoma risk in a population in central Italy: a case-control study. Melanoma Res 2006; 16: 175-82.
6. Fernandez L, Milne R, Bravo J, et al. MC1R: three novel variants identified in a malignant melanoma association study in the Spanish population. Carcinogenesis 2007; 28: 1659-64.
7. Gerstenblith MR, Goldstein AM, Fargnoli MC, et al. Comprehensive evaluation of allele frequency differences of MC1R variants across populations. Hum Mutat 2007; 28: 495-505.
8. Scherer D, Nagore E, Bermejo JL, et al. Melanocortin receptor 1 variants and melanoma risk: a study of 2 European populations. Int J Cancer 2009; 125: 1868-75.
9. Smith R, Healy E, Siddiqui S, et al. Melanocortin 1 receptor variants in an Irish population. J Invest Dermatol 1998; 111: 119-22.
10. Bastiaens MT, ter Huurne JA, Kielich C, et al. Melanocortin-1 receptor gene variants determine the risk of nonmelanoma skin cancer independently of fair skin and red hair. Am J Hum Genet 2001; 68: 884-94.
11. Stratigos AJ, Dimisianos G, Nikolaou V, et al. Melanocortin receptor-1 gene polymorphisms and the risk of cutaneous melanoma in a low-risk southern European population. J Invest Dermatol 2006; 126: 1842-9.
12. Ibarrola-Villava M, Fernandez LP, Pita G, et al. Genetic analysis of three important genes in pigmentation and melanoma susceptibility: CDKN2A, MC1R and HERC2/OCA2. Exp Dermatol 2010; 19: 836-44.
13. Douki T, Reynaud-Angelin A, Cadet J, et al. Bipyrimidine photoproducts rather than oxidative lesions are the main type of DNA damage involved in the genotoxic effect of solar UVA radiation. Biochemistry 2003; 42: 9221-6.
14. Rochette PJ, Therrien JP, Drouin R, et al. UVA-induced cyclobutane pyrimidine dimers form predominantly at thymine-thymine dipyrimidines and correlate with the mutation spectrum in rodent cells. Nucleic Acids Res 2003; 31: 2786-94.
15. Dahle J, Kvam E,. Induction of delayed mutations and chromosomal instability in fibroblasts after UVA-, UVB-, and X-radiation. Cancer Res 2003; 63: 1464-9.
16. Baars AJ, Breimer DD,. The glutathione S-transferases: their role in detoxification and toxification of xenobiotics. Ann Biol Clin (Paris) 1980; 38: 49-56.
17. Lusini L, Tripodi SA, Rossi R, et al. Altered glutathione anti-oxidant metabolism during tumor progression in human renal-cell carcinoma. Int J Cancer 2001; 91: 55-9.
18. Nebert DW, Vasiliou V,. Analysis of the glutathione S-transferase (GST) gene family. Hum Genomics 2004; 1: 460-4.
19. Moral A, Palou J, Lafuente A, et al. Immunohistochemical study of alpha, mu and pi class glutathione S transferase expression in malignant melanoma. MMM Group. Multidisciplinary Malignant Melanoma Group. Br J Dermatol 1997; 136: 345-50.
20. Reich K, Westphal G, Schulz T, et al. Combined analysis of polymorphisms of the tumor necrosis factor-alpha and interleukin-10 promoter regions and polymorphic xenobiotic metabolizing enzymes in psoriasis. J Invest Dermatol 1999; 113: 214-20.
21. Mossner R, Anders N, Konig IR, et al. Variations of the melanocortin-1 receptor and the glutathione-S transferase T1 and M1 genes in cutaneous malignant melanoma. Arch Dermatol Res 2007; 298: 371-9.
22. Heagerty AH, Fitzgerald D, Smith A, et al. Glutathione S-transferase GSTM1 phenotypes and protection against cutaneous tumours. Lancet 1994; 343: 266-8.
23. Lafuente A, Molina R, Palou J, et al. Phenotype of glutathione S-transferase Mu (GSTM1) and susceptibility to malignant melanoma. MMM Group. Multidisciplinary Malignant Melanoma Group. Br J Cancer 1995; 72: 324-6.
24. Shanley SM, Chenevix-Trench G, Palmer J, et al. Glutathione S-transferase GSTM1 null genotype is not overrepresented in Australian patients with nevoid basal cell carcinoma syndrome or sporadic melanoma. Carcinogenesis 1995; 16: 2003-4.
25. Kanetsky PA, Holmes R, Walker A, et al. Interaction of glutathione S-transferase M1 and T1 genotypes and malignant melanoma. Cancer Epidemiol Biomarkers Prev 2001; 10: 509-13.
26. Dolzan V, Rudolf Z, Breskvar K,. Genetic susceptibility to environmental carcinogenesis in Slovenian melanoma patients. Acta Dermatovenerol Alp Panonica Adriat 2006; 15: 69-78.
27. Bu H, Rosdahl I, Holmdahl-Kallen K, et al. Significance of glutathione S-transferases M1, T1 and P1 polymorphisms in Swedish melanoma patients. Oncol Rep 2007; 17: 859-64.
28. Hanada K, Ishikawa H, Tamai K, et al. Expression of glutathione S-transferase-pi in malignant skin tumors. J Dermatol Sci 1991; 2: 18-23.
29. Singhal SS, Saxena M, Awasthi S, et al. Glutathione S-transferases of human skin: qualitative and quantitative differences in men and women. Biochim Biophys Acta 1993; 1163: 266-72.
30. Ali-Osman F, Akande O, Antoun G, et al. Molecular cloning, characterization, and expression in Escherichia coli of full-length cDNAs of three human glutathione S-transferase Pi gene variants. Evidence for differential catalytic activity of the encoded proteins. J Biol Chem 1997; 272: 10004-12.
31. Srivastava DS, Mishra DK, Mandhani A, et al. Association of genetic polymorphism of glutathione S-transferase M1, T1, P1 and susceptibility to bladder cancer. Eur Urol 2005; 48: 339-44.
32. Ye Z, Song H,. Glutathione S-transferase polymorphisms (GSTM1, GSTP1 and GSTT1) and the risk of acute leukaemia: a systematic review and meta-analysis. Eur J Cancer 2005; 41: 980-9.
33. Sun XF, Ahmadi A, Arbman G, et al. Polymorphisms in sulfotransferase 1A1 and glutathione S-transferase P1 genes in relation to colorectal cancer risk and patients' survival. World J Gastroenterol 2005; 11: 6875-9.
34. Nie F, Chen Z, Cao C, Cen Y,. Absence of association between GSTM1 and GSTT1 polymorphisms and melanoma susceptibility: a meta-analysis. DNA Cell Biol 2011; 30: 783-8.
35. Fortes C, Mastroeni S, Boffetta P, et al. Polymorphisms of GSTM1 and GSTT1, sun exposure and the risk of melanoma: a case-control study. Acta Derm Venereol (Stockh) 2011; 91: 284-9.
36. Townsend DM, Tew KD,. The role of glutathione-S-transferase in anti-cancer drug resistance. Oncogene 2003; 22: 7369-75.
37. Yang G, Shu XO, Ruan ZX, et al. Genetic polymorphisms in glutathione-S-transferase genes (GSTM1, GSTT1, GSTP1) and survival after chemotherapy for invasive breast carcinoma. Cancer 2005; 103: 52-8.
38. Sturm RA, Teasdale RD, Box NF,. Human pigmentation genes: identification, structure and consequences of polymorphic variation. Gene 2001; 277: 49-62.
39. Duffy DL, Zhao ZZ, Sturm RA, et al. Multiple pigmentation gene polymorphisms account for a substantial proportion of risk of cutaneous malignant melanoma. J Invest Dermatol 2010; 130: 520-8.
40. Duffy DL, Box NF, Chen W, et al. Interactive effects of MC1R and OCA2 on melanoma risk phenotypes. Hum Mol Genet 2004; 13: 447-61.